Revelation Biosciences, Inc.
REVB· Nasdaq
Released Apr 15, 2022, after the close
10-K filed Apr 15, 2022, 105 days after period end · 0001213900-22-020179
derived · Computed from the longer spans the company filed.
No earnings release is on file for this quarter. Its figures came with the 10-K.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|
| Net Income | -$3.86M | -$1.62M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Apr 15, 2022 · 105 d after period end
+6.1% from the close of Apr 13, 2022 to the close of Apr 20, 2022, the first after the release.